Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05394142
Other study ID # SPIOMET4HEALTH
Secondary ID 2021-003177-58
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 24, 2022
Est. completion date April 2025

Study information

Verified date April 2024
Source Fundació Sant Joan de Déu
Contact Rita Malpique, PhD
Phone +34936 00 97 51
Email rita.malpique@sjd.es
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-centre, multi-national, double-blinded, placebo-controlled, parallel, randomised Phase II clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone and Metformin (SPIOMET) for adolescent girls and young adult women with polycystic ovary syndrome. Study description: Currently, there is no European Medicines Agency /U.S. Food and Drug Administration (FDA)-approved therapy for polycystic ovary syndrome in adolescent girls and young adult women. Oral contraceptives (OCs) are prescribed off-label to approximately 98% of AYAs with PCOS, including those without pregnancy risk. OCs alleviate key symptoms by inducing a pharmacological combination of anovulatory subfertility, regular pseudo-menses, and extreme elevations of sex hormone-binding globulin (SHBG), but OCs do not revert the underlying pathophysiology, and patients remain at risk for post-treatment subfertility and possibly, for lifelong co-morbidities. Given the key role of hepato-visceral fat excess in the pathogenesis of PCOS, the prime aim of the treatment should be to achieve a preferential loss of central fat, which should in turn normalise the entire PCOS phenotype. Recent evidence disclosed that a treatment consisting of a fixed low-dose combination of two insulin sensitisers [pioglitazone (PIO) and metformin (MET), with different modes of action], and one mixed anti-androgen and anti-mineralocorticoid (spironolactone), was superior to an OC in normalising the PCOS phenotype, including ovulation rates and hepato-visceral fat. The study's main goals are to assess the efficacy, tolerability and safety of a new treatment (SPIOMET) for adolescent girls and young adult women with polycistic ovarian syndrome; the comparison (in this order) of each SPIOMET, spironolactone and pioglitazone (SPIO) and PIO over placebo; and in addition, the comparison of SPIOMET over PIO and over SPIO (in this order). Primary Objective: To test the efficacy of SPIOMET in normalising ovulation rate in adolescents and young adult women with PCOS. Secondary Objectives: To test the efficacy of SPIOMET in normalising the endocrine-metabolic status, to describe the drug safety profile and to assess the adherence and subjective acceptability, as well as the quality of life of the participating subjects.


Description:

This is a multi-centre, multi-national, double-blinded, placebo-controlled, parallel, randomised Phase II clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone and Metformin (SPIOMET) for adolescent girls and young adult women (AYAs) with polycystic ovary syndrome (PCOS). Study description: Currently, there is no European Medicines Agency (EMA)/U.S. Food and Drug Administration (FDA)-approved therapy for PCOS in AYAs. Oral contraceptives (OCs) are prescribed off-label to approximately 98% of AYAs with PCOS, including those without pregnancy risk. OCs alleviate key symptoms by inducing a pharmacological combination of anovulatory subfertility, regular pseudo-menses, and extreme elevations of sex hormone-binding globulin (SHBG), but OCs do not revert the underlying pathophysiology, and patients remain at risk for post-treatment subfertility and possibly, for lifelong co-morbidities. Given the key role of hepato-visceral fat excess in the pathogenesis of PCOS, the prime aim of the treatment should be to achieve a preferential loss of central fat, which should in turn normalise the entire PCOS phenotype. Recent evidence disclosed that a treatment consisting of a fixed low-dose combination of two insulin sensitisers [pioglitazone (PIO) and metformin (MET), with different modes of action], and one mixed anti-androgen and anti-mineralocorticoid (spironolactone), was superior to an OC in normalising the PCOS phenotype, including ovulation rates and hepato-visceral fat.


Recruitment information / eligibility

Status Recruiting
Enrollment 364
Est. completion date April 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender Female
Age group 12 Years to 23 Years
Eligibility Inclusion Criteria: 1. Age range within the AYAs category (> 12.0 years and = 23.9 years at study start) (96); Given that another inclusion criterium is gynaecological age (years elapsed since menarche) of 2 years or more, and that menarche before age 10.0 years is an exclusion criterium (please see exclusion criteria below), the youngest participant will be older than 12.0 years at study start (97). The upper age limit at study start is set at 23.9 years (thus, 24.9 years when the active treatment ends, see section 7. Conduct), in order to avoid early dropouts due to an increase in the prevalence of pregnancy wish beyond that age in most European countries; 2. Gynaecological age of 2 years or more; 3. Clinical androgen excess, as defined by the presence of hirsutism (modified Ferriman-Gallwey score = 4) (17,98) and/or inflammatory acne (Leeds scale) unresponsive to medications (3,95,99). The scarce normative data existing in adolescents suggest that an adult level of hirsutism is reached around 2 years after menarche (100); 4. Biochemical androgen excess, as defined by increased total testosterone (=50 ng/dL), and/or a FAI higher than 3.5 [FAI, total testosterone (nmol/L) x 100/SHBG (nmol/L)], in the follicular phase of the cycle (days 3-7) or after 2 months of amenorrhea (3,100,101); Measurements of total testosterone and/or FAI are the most recommended assessments to screen for hyperandrogenaemia (3,19,95,102). Serum testosterone attains adult levels shortly after menarche; thus, an elevation of serum testosterone concentrations and/or FAI above adult norms and assessed in reliable reference laboratories constitutes biochemical evidence of hyperandrogenism (3,19,95,100). It is accepted that this upper limit can be set at 45 ng/dL for testosterone and at 3.5 for FAI (3,95,100,101,102,103). Direct free testosterone assays, such as radiometric or enzyme-linked assays, preferably should not be used in the assessment of biochemical hyperandrogenism, as they demonstrate poor sensitivity, accuracy and precision (17); 5. Menstrual irregularity, as defined by = 8 menses per year corresponding to an average inter-menstrual time of =45 days (3,95,100); Most adolescents establish a menstrual interval of 20-45 days within the first 2 years after menarche (3,95). Three years after menarche, the 95th percentile for cycle length is 43.6 days (104); thus, cycles longer than 45 days (<8 periods/year) at or beyond this gynaecological age are considered abnormal and are evidence of oligo-anovulation; 6. Written informed consent obtained from the patient, or assent from the patient and consent by the parents or the legally acceptable representative if she is a minor (for details, see section 7. Conduct, under informed consent). Exclusion Criteria: -

Study Design


Intervention

Drug:
Placebo
Comparator arm with placebo
Pioglitazone
Pioglitazone 7.5 mg/day
Spironolactone
Spironolactone 50 mg/day
Metformin
Metformin 850 mg/day

Locations

Country Name City State
Austria Universitätsklinik für Innere Medizin Graz
Denmark Odense University Hospital (UNIODE) Odense
Italy Azienda Ospedaliero Universitaria di Bologna Bologna
Norway St. Olavs Hospital Trondheim
Spain Hospital Sant Joan de Deu Esplugues De Llobregat
Spain Hospital Universitari de Girona Dr. Trueta Girona
Turkey Istanbul Faculty of Medicine Topkapi Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Fundació Sant Joan de Déu

Countries where clinical trial is conducted

Austria,  Denmark,  Italy,  Norway,  Spain,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary On-treatment ovulation rate. On-treatment ovulation rate. Following end of each two 12-week on-treatment periods (month 0-3 and month 9-12)
Primary Post-treatment ovulation rate. Post-treatment ovulation rate. Following the end of post-treatment period (month 12-15)
Secondary Clinical variable: hirsutism Presence of hirsutism as measured by the modified Ferriman & Gallwey score Every 3 months from study start to study completion (estimated 18 months)
Secondary Clinical variable: Acne Presence of Acne as evaluated using the Leeds Acne Grading Scale Every 3 months from study start to study completion (estimated 18 months)
Secondary Clinical variable: menstrual regularity Assessment of the menstrual regularity Every 3 months from study start to study completion (estimated 18 months)
Secondary Circulating androgens Assessment by measurement of circulating androgens Every 3 months from study start to study completion (estimated 18 months)
Secondary Lipids Assessment by measurement of total cholesterol, low-density lipoprotein (LDL-cholesterol), high-density lipoprotein (HDL- cholesterol), triglycerides; Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary Insulinaemia Fasting and 2 hours after a 75-gr oral glucose load [oral glucose tolerance test (oGTT). Estimation of insulin resistance from fasting insulin and glucose levels using the homeostasis model assessment (HOMA); Baseline and at the end of treatment (month 12) and 6 months after treatment
Secondary Inflammation markers Inflammation markers Baseline and at the end of treatment (month 12) and 6 months after treatment
Secondary Insulin sensitivity Insulin sensitivity Baseline and at the end of treatment (month 12) and 6 months after treatment
Secondary Ultra-sensitive C-reactive protein (us-CRP); Ultra-sensitive C-reactive protein (us-CRP); Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary Growth-and- differentiation factor-15 (GDF15); Growth-and- differentiation factor-15 (GDF15); Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary High molecular weight adiponectin (HMW-adip), High molecular weight adiponectin (HMW-adip), Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary C-X-C motif chemokine ligand 14 (CXCL14) (69,81); C-X-C motif chemokine ligand 14 (CXCL14) (69,81); Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary Epigenetic variable Circulating microRNA 451-a (miR-451a) concentrations (88); Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary Imaging: Cardiovascular risk As measured by ultrasound Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary Imaging: Body composition As measured by dual-energy X-ray absorptiometry (DXA) Baseline and at the end of treatment (month 12) and 6 months after treatment
Secondary Imaging: Abdominal fat distribution (subcutaneous and visceral) As measured by MRI Baseline and at the end of treatment (month 12) and 6 months after treatment
Secondary Imaging:hepatic fat As measured by MRI Baseline and at the end of treatment (month 12) and 6 months after treatment
Secondary Abdominal fat distribution Waist circumference, Waist to hip ratio (WHR), and hepatic fat by MRI Baseline and at the end of treatment (month 12) and 6 months after treatment
Secondary Weight Weight measurement Every 3 months from study start to study completion (estimated 18 months)
Secondary Improvement of co-morbidities Improvement of co-morbidities Every 3 months from study start to study completion (estimated 18 months)
Secondary Improvement of health behaviour Improvement of health behaviour Every 3 months from study start to study completion (estimated 18 months)
Secondary Improvement of health-related quality of life (HRQoL) As reported by the patient Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary Safety laboratory tests Blood count, electrolyte panel, urea, alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyltransferase (GGT), creatinine, vitamin B12 and folic acid; Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary Adverse events (AEs) As reported by the patient Every 3 months from study start to study completion (estimated 18 months)
Secondary Adherence Adherence will be calculated as the ratio between the number of tablets prescribed and dispensed for the period between hospital appointments and the number of tablets returned by the patient at the following appointment; Every 3 months from study start to study completion (estimated 18 months)
Secondary Acceptability of the treatment Acceptability of the tablet by the study patients Every 3 months from study start to study completion (estimated 18 months)
Secondary PROMs (patient-reported outcomes) Questionnaire SF-36 Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary PROMs (patient-reported outcomes) Questionnaire PCOSQ Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary HRQoL (health-related quality of life) Questionnaire SF-36 Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary HRQoL (health-related quality of life) Questionnaire PCOSQ Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT06306417 - A Randomized Controlled Trial of Acupuncture for Insulin Resistance in Patients With Polycystic Ovary Syndrome N/A
Completed NCT01927471 - Nutritional and Metabolic Correlates of Ovarian Morphology in Women With Polycystic Ovary Syndrome
Completed NCT01927432 - Ultrasound Characterization of Ovarian Follicle Dynamics in Women With Amenorrhea
Completed NCT00805207 - Sex Steroids, Sleep, and Metabolic Dysfunction in Women N/A
Completed NCT01999686 - PCOS Treatment Using DLBS3233, Metformin, and Combination of Both Phase 3
Completed NCT03414957 - Malay Women With PCOS and Their Association With Metabolic Syndrome
Recruiting NCT06143527 - Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for PCOS Phase 1
Completed NCT01233206 - Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles Phase 4
Not yet recruiting NCT05272657 - Low-Carb Versus Mediterranean Diet in PCOS N/A
Completed NCT01733459 - Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS) Phase 3
Completed NCT04264832 - Body Fat Distribution and Its Associated Factors in Chinese Women With Polycystic Ovary Syndrome
Completed NCT03547453 - Ovarian Ultrasonography for the Clinical Evaluation of Polycystic Ovary Syndrome
Terminated NCT02865915 - MLE4901 vs. Placebo for the Treatment of PCOS Phase 2
Completed NCT02429128 - 14 Weeks Exercise Training on Lean Women With and Without PCOS N/A
Completed NCT01899001 - Mood and Nutrition Interventions in Polycystic Ovary Syndrome N/A
Completed NCT03151005 - The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS Phase 4
Completed NCT03792282 - Time-Restricted Feeding(TRF) on Overweight/Obese Women With Polycystic Ovarian Syndrome (PCOS) N/A
Completed NCT04852510 - Amelioration of Polycystic Ovary Syndrome Related Disorders by Supplementation of Thymoquinone and Metformin Phase 2/Phase 3
Recruiting NCT05200793 - Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome Phase 4
Not yet recruiting NCT01720459 - Effects of Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients N/A